The mechanism by which the E6 protein of human papillomavirus type 16 (HPV-16) transactivates heterologous virus promoters has not been established. In this study, the involvement of p53-mediated transcriptional repression in transactivation by the HPV-16 E6 protein was examined using several virus promoters. HPV-16 E6 transactivated the TATA box-containing simian virus 40 early promoter and the Rous sarcoma virus long terminal repeat in p53-containing cells but not in p53-deficient cells. In contrast, the adenovirus E2 promoter was transactivated both in p53-containing and p53-deficient cells. These results indicate that the transactivation activity of the HPV-16 E6 protein is mediated by p53-dependent and promoter-specific p53-independent pathways.
Human papillomaviruses (HPVs) are small DNA tumour viruses that induce epithelial cell proliferation. So far, over 60 different types of HPV have been identified (de Villiers, 1994) . Certain types, such as HPV-16 and HPV-18, are associated with human anogenital cancers and are thought to play a role in carcinogenesis. Co-operation between the E6 and E7 gene products of high-risk HPVs such as HPV-16 and HPV-18, but not low-risk HPVs such as HPV-6 and HPV-11, is required for effective immortalization of primary human keratinocytes (Miinger et al., 1989; Hawley-Nelson et al., 1989; Hudson et al., 1990) .
The E6 protein of HPV-16 has been shown to bind and promote degradation of the p53 protein through the ubiquitin-dependent protease system Scheffner et al., 1990) . In addition, the HPV-16 E6 protein transactivates heterologous virus promoters, such as adenovirus E2, herpes simplex virus thymidine kinase gene promoters, human immunodeficiency virus long terminal repeat, adenovirus major late and simian virus 40 (SV40) early promoters (Sedman et al., 1991; Desaintes et al., 1992; Shirasawa et al., 1994) .
The mechanism by which the HPV-16 E6 protein transactivates heterologous promoters has not yet been established. Since the p53 protein represses transcription from TATA box-containing promoters (Mack et al., * Author for correspondence. Fax +81 43 226 2045. e-mail simizu @med.m.chiba-u.ac.jp 1993) and HPV-16 E6 protein is able to abrogate p53-mediated transcriptional repression (Lechner et al., 1992) , transactivation by E6 may be mediated through relieving repression by the p53 protein. However, HPV-16 E6 mutants deficient in p53-binding and p53-degradation were shown to have transactivation activity (Crook et al., 1991) , suggesting that this activity of HPV-16 E6 is independent of p53. To explain these observations, it may be assumed that the transactivation mechanism of the HPV-16 E6 protein consists of p53-dependent and -independent pathways. To test this, we examined the two activities. Here we demonstrate that HPV-16 E6 transactivates the SV40 early promoter and Rous sarcoma virus (RSV) long terminal repeat (LTR) in a p53-dependent pathway and that the adenovirus E2 promoter is transactivated by the E6 at least in a p53-independent pathway. Our results provide direct evidence that transactivation of promoters by HPV-16 E6 involves multiple independent pathways.
Expression of p53 in two human lung cancer-derived cell lines was examined prior to transfection experiments. Northern blot analysis showed that LU99 cells (Yamada et al., 1985) expressed the p53 mRNA and NCI-H358 cells (Brower et al., 1986; Takahashi et al., 1989) had no detectable p53 mRNA (Fig. 1 a) . To see whether LU99 cells expressed wild-type p53 mRNA, single-strand conformational polymorphism (SSCP)-PCR of the p53 cDNA was done. First-strand cDNAs of p53 mRNA were synthesized from 5 lag of total RNA with a primer NA01 (5' TAAAGCTTATGGAGGAGCCGCAGTC-0001-3607 © 1996 SGM 3) and NCI-H358 cells (lanes 2 and 4) were immunoprecipitated by p53 antibody PAbl801 (pan-reactive p53 monoclonal antibody; lanes 1 and 2) and PAb240 (specific-reactive for mutated p53 conformation; lanes 3 and 4), followed by SDS PAGE (10%) and autoradiography. An arrowhead indicates the retained p53 protein.
AGAT 3') by reverse transcriptase (Superscript II; Life Technologies). Next, 5% of the first-strand cDNA reaction was amplified in a volume of 5 gl containing 50 mM-KC1, l0 mM-Tris-HC1 pH 8'3, 1'5 mM-MgC12, 0.01% (w/v) gelatin, 1.25 mM each of four dNTPs, 0.2 gg of primers NA01 and NA02 (5' GGTCTAGA-GTCAGTGGGGAACAAGAAG 3'), 0.25 units of Taq DNA polymerase (Perkin Elmer) and 0.5 lal of [~-a~P]dCTP (10 mCi/ml). The PCR consisted of denaturing (94 °C, 1 rain), annealing (60 °C, 2 rain) and extension (72 °C, 2-5 rain) for 30 cycles on an OmniGene Temperature Cycler (Hybaid). The PCR reaction, digested with AfaI, was mixed with loading buffer (95% formamide, 20 mM-EDTA, 0'05 % xylene cyanol, 0-05 % bromophenol blue), incubated at 90 °C for 5 min, cooled on ice immediately and loaded onto a 6% polyacrylamide gel containing 1 x TBE (89 mM-Tris-borate, 2 mM-EDTA pH 8"3) and 10% glycerol. The gel was run at 4 °C using 1 x TBE as a running buffer, dried and autoradiographed. As shown in Fig. 1 (b) , the p53 cDNA of LU99 cells showed the same mobility as the wild-type p53 cDNA. By immunoprecipitations with monoclonal antibody PAb 1801 (Oncogene Science) the wild-type p53 protein was detected in LU99 cells but not in NCI-H358 cells, and with monoclonal antibody PAb240 (Oncogene Science) no mutant p53 protein was found in either cell line (Fig. l c) . The p53 of LU99 and another lung carcinoma cell line IA (Shirasawa et al., 1994) was also confirmed to be wild-type by sequencing PCR-amplified p53 gene exons (data not shown).
Reporter plasmids pE2cat, pCATpromoter and pRSVLacZ were used in this study, pE2cat and pCATpromoter contain the adenovirus type 5 E2 gene promoter and SV40 early promoter, respectively, upstream of the chloramphenicol acetyltransferase (CAT) gene (Murthy et al., 1985; Shirasawa et al., 1994) . pRSVLacZ contains the RSV LTR upstream of the lacZ gene. Human wild-type p53 expression plasmid pC53SN3 (Baker et al., 1990) was obtained from Dr B. Vogelstein (Johns Hopkins University, Baltimore, Md., USA). The p53 expression plasmids employed the cytomegalovirus promoter/enhancer and the SV40 early region polyadenylation signal. An expression plasmid pRSVE6m, which does not express E6*I but only fulllength E6 mRNA and protein, was constructed as previously described (Shirasawa et al., 1994) .
To examine if the transactivation activity of HPV-16 E6 is dependent on p53, reporter plasmids containing the adenovirus E2 promoter, SV40 promoter or RSV LTR, and the E6 expression plasmid were cotransfected into NCI-H358 cells, which express no detectable p53. As shown in Fig. 2(a) , the SV40 promoter and RSV LTR were not transactivated by HPV-16 E6 in the p53-deficient NCI-H358 cells, indicating that they are not transactivated by E6, at least in the absence of p53. In contrast, the adenovirus E2 promoter in NCI-H358 cells was transactivated by E6 in a dose-dependent manner.
To see if HPV-16 E6 can transactivate the SV40 promoter and RSV LTR in cells which express endogenous wild-type p53, a fixed amount of reporter plasmids was cotransfected with increasing amounts of pRSVE6m into LU99 cells, which express wild-type p53. As shown in Fig. 2(b) , the SV40 promoter and RSV LTR, as well as the adenovirus E2 promoter, were transactivated by HPV-16 E6 in the presence of endogenous wild-type p53, suggesting that the SV40 promoter and RSV LTR are transactivated by HPV-16 E6 in the presence of p53. A similar extent of transactivation of adenovirus E2 and SV40 early promoters by E6 was also observed in another lung carcinoma cell line, IA, which has wild-type p53 (data not shown). As E6 is expressed from the RSV LTR, the dose response in this experiment might be exaggerated.
Because HPV-16 E6 protein has been shown to abrogate exogenously supplied p53-mediated repression of transcription from the SV40 promoter (Lechner et 1992), transactivation of promoters by HPV-16 E6 may be mediated by relieving the transcriptional repression by p53. To test the effect of HPV-16 E6 on p53-mediated transcriptional repression, NCI-H358 cells were transfected with the adenovirus E2 promoter, SV40 promoter or RSV LTR together with the p53 expression plasmid pC53SN3 and the E6 expression plasmid pRSVE6m. As shown in Fig. 3(a) , the adenovirus E2 and SV40 promoters were repressed by p53. The RSV LTR was also repressed by p53 (data not shown). To demonstrate that the SV40 promoter and RSV LTR can be transactivated by HPV-16 E6 through abrogation of p53-mediated repression, NCI-H358 cells were transfected with each reporter plasmid, pRSVE6m and pC53SN3. Because HPV-16 E6 has a two-to threefold repressive effect on the cytomegalovirus promoter of the p53 expression plasmid pC53SN3 (Etscheid et al., 1994) , a sufficient amount of pC53SN3 was cotransfected. As the repression effect of pC53SN3 on promoters reaches a plateau at 0.2 to 1 gg (data not shown), 5 gg ofpC53SN3 were transfected. As shown in Fig. 3 (a, b) , the SV40 and RSV LTR promoters were transactivated by HPV-16 E6 in the presence of exogenously supplied p53. The effect of E6 on p53 might be underestimated due to the repressive effect of p53 on the RSV LTR of the E6 expression plasmid pRSVE6m. The mechanism by which HPV E6 proteins transactivate virus promoters has not yet been completely established. However, our study revealed that at least two mechanisms are involved in this activity.
It has been shown that HPV-16 E6 abrogates the transcriptional repression of the SV40 promoter mediated by exogenously supplied p53 (Lechner et al., 1992) , suggesting that the transactivation activity of HPV-16 E6 may represent the inhibition of transcriptional repression by endogenous p53. However, there was the possibility that E6 can transactivate the SV40 early promoter by p53-independent pathways. Our study has demonstrated that HPV-16 E6 relieves endogenous p53-dependent transcriptional repression of the TATA box-containing SV40 early promoter and RSV LTR, and that both of these promoters are not transactivated by p53-independent pathways. It was also suggested that the HPV-16 E6 protein would generally transactivate TATA box-containing promoters by p53-dependent pathways.
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